After FDA snub, EMA backs FibroGen, Astellas’ roxadustatThe EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease Share XAfter FDA snub, EMA backs FibroGen, Astellas’ roxadustathttps://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/
FDA rejects FibroGen/AZ’s roxadustat, asking for new trialThe FDA has demanded another clinical trial of FibroGen and AstraZeneca’s roxadustat for anaemia caused by chronic kidney Share XFDA rejects FibroGen/AZ’s roxadustat, asking for new trialhttps://pharmaphorum.com/news/fda-rejects-fibrogen-azs-roxadustat-asking-for-new-trial/
FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiaSafety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for Share XFDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiahttps://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/
Astellas gets nod in Japan for roxadustat, ahead of GSK rivalAstellas has its first approval for roxadustat, getting a green light in Japan for the drug as a Share XAstellas gets nod in Japan for roxadustat, ahead of GSK rivalhttps://pharmaphorum.com/news/astellas-gets-nod-in-japan-for-roxadustat-ahead-of-gsk-rival/
